Medicine information
Uses & overview
Dapavilda 50-5 is a Steris Healthcare Tablet listed in the Diabetes range. Its verified composition is Dapagliflozin (5mg), Vildagliptin SR (50mg). The available product record lists the pack as For 15 Tablets. The official product information describes its intended clinical use as follows: DAPA VILDA 50/5 Blood Sugar Control: Helps in regulating high blood sugar levels in adults with type 2 diabetes. Complementary Therapy: Can be used alongside diet and exercise or with other medications to achieve optimal glycemic control. Reducing Complications: Aims to lower the risk of diabetes-related complications such as cardiovascular diseases. What is DAPA VILDA 50/5? DAPA VILDA 50/5 is a combination oral tablet containing 5mg of Dapagliflozin and 50mg of Vildagliptin in a sustained-release formulation. It is prescribed for the management of type 2 diabetes to improve glycemic control. Side Effects Common Side Effects: Urinary tract infections Nasopharyngitis Headache Dizziness Serious Side Effects: Severe hypoglycemia Pancreatitis Kidney problems Allergic reactions Safety Information Hydration: Ensure adequate fluid intake to prevent dehydration due to increased urination… A valid prescription is required. The prescribing clinician decides the dose, duration and suitability based on the patient’s condition and medical history.
How to use
Use Dapavilda 50-5 only by the route intended for this Tablet. Follow the exact dose and duration prescribed by your doctor. Do not exceed the recommended amount, and do not share the product with another person.
Storage
Keep Dapavilda 50-5 in its original pack and follow the storage temperature printed on the label. Protect it from excess heat, moisture and direct sunlight, and keep it out of the reach of children.
